Ondero D 10 mg, which contains Linagliptin and Dapagliflozin, is generally not recommended for patients with an eGFR (estimated glomerular filtration rate) as low as 12 mL/min/1.73m², especially in CKD (chronic kidney disease) stage 4.

⚕️ Use in CKD Stage 4 with eGFR 12

• Dapagliflozin (a sodium-glucose cotransporter-2 inhibitor) is usually avoided or used with caution when eGFR is below 30, as its effectiveness decreases and risk of side effects increases.
• Linagliptin (a dipeptidyl peptidase-4 inhibitor) can be used in CKD but dose adjustments and close monitoring are necessary.
• At eGFR 12, kidney function is severely reduced, so medication choices must be carefully tailored to avoid worsening kidney damage or other complications.

🩺 Recommendations

• Consult a nephrologist (kidney specialist) and an endocrinologist (diabetes specialist) before using Ondero D 10 mg in this context.
• Alternative diabetes treatments safer for advanced CKD may be considered.
• Regular monitoring of kidney function and blood sugar is essential.

If you want, I can explain more about safer diabetes management options in advanced CKD.